^
    Back
    Association details:
    Biomarker:BRCA wild-type + TP53 mutation
    Cancer:Ovarian Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Gene Ther
    Title:

    Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

    Published date:
    11/16/2021
    Excerpt:
    Improved relapse free survival in Vigil treated patients was found for the TP53m-BRCAwt-HRP group compared to placebo (21.1 months versus 5.6 months p = 0.0013). Results suggest a subset of ovarian cancer patients with enhanced susceptibility to Vigil immunotherapy.
    DOI:
    10.1038/s41417-021-00400-x